Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
about
Improving the clinical impact of biomaterials in cancer immunotherapy.Single-cell analysis tools for drug discovery and developmentAdoptive T Cell Therapy Targeting CD1 and MR1Antigen-specific T cells fully conserve antitumour function following cryopreservation.Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationClients and Oncogenic Roles of Molecular Chaperone gp96/grp94Recent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsT cell engineering as therapy for cancer and HIV: our synthetic futureDesigning chimeric antigen receptors to effectively and safely target tumorsWhole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancerProtection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.Multifunctional cytomegalovirus (CMV)-specific CD8(+) T cells are not restricted by telomere-related senescence in young or old adults.Reprogramming antitumor immunityAkt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.T Cell Vaccinology: Beyond the Reflection of Infectious ResponsesEnhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic ImmunityEngineering T cells for cancer: our synthetic future.Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.Targeting T cell metabolism for therapy.T cell optimization for the treatment of pancreatic cancer.IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelCD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.IL-21 Augments Rapamycin in Expansion of Alpha Fetoprotein Antigen Specific Stem-Cell-like Memory T Cells in vitro.Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity.Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.Current challenges for cancer vaccine adjuvant development.A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy.AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8 T cells for adoptive immunotherapy
P2860
Q26766267-54B3B3C1-0226-445A-9EBC-34C075A4D691Q26775754-9437780B-6272-414C-85FB-B6A9121BEEFDQ26998503-3EC7A1E1-1D95-416B-9971-85CA5E40C4FFQ27323082-CE8FB60A-F13E-42F2-AC7A-C195F12A90CFQ28068378-5CF36FC8-A0D6-4995-AF9F-7D5D247DD80FQ28075479-09A5960E-2F04-4F0F-B3AD-F7ADDA54584FQ28079823-476D8B48-492F-4BA5-97BF-F92F5B23A0D0Q28082253-4F996D09-FE99-4412-A3A6-1F8B26A18EA8Q28088526-0D97D204-76FB-4094-BFD1-9CB107738FDFQ34016750-29AAE567-C791-4C5A-8065-1F4FCFD995D7Q35130794-D84CBE6A-E3FD-4E32-A112-2FF2CDFE7721Q35201953-7347649B-0C94-4597-AD10-C77EAD1122E8Q35216812-22AB9D14-9D1C-44C1-BD46-31C29D816551Q35257907-8D7BC432-EAAD-423D-A4AE-8546FF3A6FE4Q36642440-9EB5CFB4-8C27-4229-A5AF-521775BBA8F5Q36871188-91946CBE-2EB4-4F94-A41D-E65550F92228Q37162647-72566798-4236-4FF2-BD66-466602F54E7EQ37515502-968CA71B-175C-4578-AA08-64243F3CAF35Q37677403-85DB4753-3BEC-437D-91BD-1E3B456E8F8CQ38283536-64B4A2CE-B102-48BA-AC41-09F07D5F96E8Q38324388-9159B7A2-4AD7-4601-9BB4-99179E9D8A99Q38638035-7121C1B0-CAFE-45C5-86ED-5FF0C24BED98Q38719376-381BE1B5-1344-4398-94C0-C0CB27280F65Q38790694-D06E7299-6449-47B4-BD51-65571AC04BD5Q38930638-A54F6879-CDA1-4AC5-A183-FFD5C6708C3AQ39249589-BB62B219-A435-4195-AE47-06AFF2E3F48BQ40583105-D0329373-045E-4E38-9958-940D022AE21EQ40599755-5C3EB51F-DA63-40F5-A3D1-061C2682E8D4Q41495089-5D797EBE-91F1-484C-A80F-893BC5156012Q47152771-95843F51-5B9E-4FD2-8C32-F7E417E7CBE9Q47259954-BD67B4C3-7751-4DB7-9421-915A058E2E82Q48160317-E5699928-EAB1-4B21-B2B0-5B5F5CA1407DQ48184244-9795FE11-92C2-4532-9BF1-B6A09DB2DEEAQ48214652-230F3EDD-CA71-47FE-B113-486DAABD0FC7Q57135104-9CF97AA1-18C6-4393-95A0-77F16988CE4A
P2860
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@en
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@nl
type
label
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@en
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@nl
prefLabel
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@en
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@nl
P2860
P356
P1476
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
@en
P2093
Joseph G Crompton
Madhusudhanan Sukumar
P2860
P304
P356
10.1111/IMR.12135
P577
2014-01-01T00:00:00Z